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Aims Less is known about the relation between in-treatment left ventricular (LV) geometry and risk of
cardiovascular events. We assessed LV geometric patterns on baseline and annual echocardiograms
as time-varying predictors of the primary composite endpoint (cardiovascular death, stroke, and
myocardial infarction) in 937 hypertensive patients with LV hypertrophy during 4.8 years losartan- or
atenolol-based treatment in the Losartan Intervention for Endpoint reduction in hypertension (LIFE)
echocardiography substudy.
Methods and results LV geometry was determined from LV mass/body surface area and relative wall
thickness in combination. At end of the study, 52% of patients with initial LV hypertrophy had normal
geometry (P, 0.001). In particular, concentric remodelling was reduced by 82% and concentric
LV hypertrophy by 84%. Development of LV hypertrophy was seen in ,5%. In Cox regression analyses
including LV geometric patterns as time-varying variables and adjusting for treatment, Framingham
risk score, race, and time-varying systolic blood pressure, the patterns independently predicted
higher risk of primary composite endpoints [HR 2.99 (1.16–7.71) for concentric remodelling, HR
1.79 (1.17–2.73) for eccentric hypertrophy, and HR 2.71 (1.13–6.45) for concentric hypertrophy; all
P , 0.05].
Conclusion In hypertensive patients with ECG LV hypertrophy, in-treatment LV geometry by echocardio-








Left ventricular (LV) hypertrophy is a cardinal manifestation
of preclinical cardiovascular disease that strongly predicts
cardiovascular events in hypertensive patients as well as in
the general population.1,2 Previous publications have
suggested that assessment of LV geometry may add prognos-
tic information in hypertensive patients beyond assessment
of LV mass alone.1,3,4
Antihypertensive treatment induces individual changes in
LV geometry in hypertensive patients. Although lower LV
mass during antihypertensive treatment is associated with
lower rates of cardiovascular events,5 less is known about
the relation between in-treatment LV geometry during
aggressive antihypertensive therapy and risk of cardiovascu-
lar events. In particular, this has not been addressed pro-
spectively in a large randomized hypertension treatment
study.
Thus, the aim of the present analysis was to assess the
relation between in-treatment LV geometry and cardio-
vascular events during randomized losartan- or atenolol-
based antihypertensive treatment in the Losartan Interven-
tion for Endpoint reduction in hypertension (LIFE) echocar-
diography substudy.* Corresponding author. Tel: þ47 55972220; fax: þ47 55975150.
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Protocol, patient characteristics, and outcome results in the LIFE
echocardiography study and the main LIFE study have been pub-
lished.5–9 The conduct of the LIFE study complied with the Declara-
tion of Helsinki. Approval was obtained from all relevant ethics
committees. Patients provided written informed consent.
Patient population
The present analysis was prospectively planned within the LIFE
echocardiography substudy that performed annual echocardio-
graphic follow-up in 960 of the 9193 patients in the parent LIFE
trial. The LIFE study randomized hypertensive patients aged 55–80
years with baseline clinic blood pressure 160–200/95–115 mmHg
and electrocardiographic LV hypertrophy by Cornell voltage-
duration or Sokolow–Lyon voltage criteria to 4.8-year double-blind
losartan- or atenolol-based antihypertensive treatment.7 Among
the 960 patients included in the LIFE echocardiography substudy,
the present analysis was undertaken within the 937 patients with
measurable LV dimensions on the baseline echocardiogram. Com-
pared with patients excluded from the current analysis (n ¼ 23),
the present study population had lower body mass index (27.2+
4.4 vs. 30.1+6.2 kg/m2, P , 0.01), but did not differ in baseline
age, blood pressure, gender distribution, race, or prevalence of dia-
betes mellitus.
Doppler echocardiography
Echocardiograms obtained at baseline and thereafter annually in
the LIFE echocardiography study were sent to the Cornell Echocar-
diography Reading Center for interpretation by an experienced
echocardiographer. Reading was performed continuously during
the study by readers blinded to study treatment and sequence of
the echocardiogram. Left ventricular chamber dimensions and
wall thicknesses were measured following the American Society of
Echocardiography standards.10 Relative wall thickness (RWT) was
calculated at end-diastole as posterior wall thickness/internal
radius, endocardial shortening as the ratio (diastolic–systolic LV
internal diameter)/diastolic LV internal diameter, LV ejection frac-
tion by the Teichholz method, and LV mass using an autopsy-
validated formula.11–14 Left ventricular mass showed excellent
inter-study reliability in a separate study of 183 patients from the
Reading Center.15 As pre-speciﬁed in the LIFE echocardiography pro-
tocol, LV hypertrophy was assessed using LV mass/body surface and
considered present when LV mass/body surface area exceeded
116 g/m2 in men and 104 g/m2 in women.5 Increased RWT was
identiﬁed as RWT  0.43.16 Left ventricular geometry was assessed
from LV mass/body surface area and RWT in combination, dividing
patients with normal LV mass/body surface area into normal or con-
centric remodelling geometric patterns, and patients with increased
LV mass/body surface area into eccentric or concentric LV hypertro-
phy patterns, respectively.17 Midwall shortening and its relation to
circumferential end-systolic stress at the level of the LV minor
axis (stress-corrected midwall shortening) were calculated using a
previously validated formula.18,19 Aortic regurgitation was assessed
by colour Doppler using previously described four-point grading
systems.20 Heart rate was measured from the echocardiographic
recordings.
Blood pressure, diabetes, and albuminuria
Blood pressure was measured at clinical study visits. Patients were
classiﬁed as having isolated systolic hypertension if systolic blood
pressure was 140 and diastolic blood pressure was ,90 mmHg,
respectively, at baseline.21 Pulse pressure was calculated as the
difference between sitting clinic systolic and diastolic blood
pressure, and mean blood pressure as sitting diastolic blood
pressure plus one-third of pulse pressure. Serum glucose was
measured at core laboratories in the USA and Europe from venous
blood drawn at clinic visits, with comparability of measurements
documented by split-sample determination. Diabetes mellitus was
diagnosed by 1985 WHO criteria for fasting and random serum
glucose or use of hypoglycaemic medication.22 Albuminuria was
assessed as urinary albumin/creatinine ratio in spot morning urine
at baseline and considered present if the ratio exceeded 3.5 mg/
mmol.23
Statistics
Data management and analysis were performed using SPSS 13.0
(SPSS, Chicago, IL, USA) software. Data are presented as mean+
SD for continuous variables and as percentages for categorical vari-
ables. Between-group comparisons were made by x2 statistics or
unpaired Student’s t-test, as appropriate. In-treatment LV geometry
was assessed on annual study echocardiograms until the occurrence
of a cardiovascular event in patients who experienced a primary
study endpoint, and on all annual study echocardiograms until end
of the study in patients who did not experience an endpoint. The
pre-speciﬁed primary endpoint in the study was a composite
endpoint of the ﬁrst occurrence of cardiovascular death, fatal or
non-fatal stroke, and fatal or non-fatal myocardial infarction. Time-
varying Cox regression analysis was used to assess the association of
baseline and in-treatment LV geometry with the pre-speciﬁed com-
posite endpoint of the LIFE study and with individual cardiovascular
death, stroke, and myocardial infarction endpoints. The model
included indicator variables for randomized study treatment and
race and baseline LV mass/body surface area, RWT, and Framingham
risk score (based on age, gender, diabetes, smoking, and baseline
total and high-density lipoprotein cholesterol levels, systolic blood
pressure, and LV hypertrophy measured by electrocardiography)24
as ﬁxed covariates, and in-treatment LV geometric patterns and sys-
tolic blood pressure as categorical time-varying covariates.25 In sub-
sequent models, LV hypertrophy and concentric geometry as
time-varying variables or time-varying change in LV mass/body
surface area replaced the time-varying LV geometric pattern cat-
egories, and time-varying heart rate was added to the covariates.
Two-tailed P , 0.05 was considered statistically signiﬁcant both in
univariate and in multivariate analyses.
Results
At baseline, patients in the different LV geometric pattern
groups differed signiﬁcantly in age, systolic blood pressure,
and prevalence of albuminuria, whereas gender, race, body
mass index, and prevalence of diabetes or isolated systolic
hypertension did not differ with LV geometry (Table 1).
Aortic regurgitation and history of myocardial infarction or
stroke were more prevalent in the groups with LV hypertro-
phy both at baseline and at end of the study.
During 4.8 years of randomized study treatment, LV geo-
metry changed signiﬁcantly, reducing the prevalences of LV
hypertrophy and of concentric remodelling by more than
half from baseline to the ﬁnal study echocardiogram or the
last one before an endpoint (Figure 1). Of the 661 patients
with eccentric or concentric LV hypertrophy at baseline,
52% had normal geometry at ﬁnal study echocardiogram
(Table 2). In particular, concentric LV hypertrophy was
reduced by 84% (Table 2). Furthermore, of the initial 97
patients with concentric remodelling at baseline, 82% had
normal geometry. Development of LV hypertrophy was only
seen in ,5% of patients with initially normal LV mass.
Prevalence of LV hypertrophy declined prospectively in
both treatment arms, in the losartan-based group from
72% at baseline and 44% after 1 year to 33% at ﬁnal event-
free study follow-up, and in the atenolol-based group from













69% at baseline and 42% at 1 year to 35% at the ﬁnal event-
free study follow-up (both P , 0.01 within group, ns
between groups), paralleling our previous ﬁnding of
greater LV hypertrophy regression in losartan-treated
patients5 but with the lesser statistical power commonly
seen when continuous variables are replaced by dichoto-
mous ones.
At ﬁnal study follow-up, several differences in patient
characteristics among individual LV geometric patterns
were noted (Table 3). Patients who maintained LV hypertro-
phy had higher in-treatment systolic blood pressure
and included more patients with aortic regurgitation (both
P , 0.05). In particular, patients who maintained concentric
remodelling included more African American patients
and more patients with diabetes and albuminuria (all
P , 0.001) (Table 3) and 38% obese patients (P ¼ 0.052 vs.
other in-treatment LV geometric pattern groups). The
numerical greater reduction of hypertrophy prevalence (by
39 vs. 33%) in patients treated with losartan- vs. atenolol-
based therapy did not attain statistical signiﬁcance.
Furthermore, in-treatment LV mass/body surface area did
not differ between the normal geometry and concentric
remodelling groups at ﬁnal study echocardiogram, while,
compared with the eccentric LV hypertrophy group, con-
centric LV hypertrophy had signiﬁcantly higher LV mass/
body surface area at ﬁnal study echocardiogram (P , 0.01)
(Table 3).
A total of 105 primary endpoints (combined cardiovascular
death, stroke, and myocardial infarction) occurred during
the mean 4.8 years of follow-up. Baseline LV geometry did
not predict outcome (P . 0.3). To assess the association of
in-treatment LV geometry with outcome, time-varying Cox
regression models were used. In the ﬁrst model including
concentric geometry and LV hypertrophy together with sys-
tolic blood pressure as time-varying covariates and study
treatment allocation and Framingham risk score as ﬁxed
covariates, in-treatment concentric geometry was associ-
ated with higher risk of combined cardiovascular events
[HR 2.36 (1.24–4.48), P ¼ 0.031] independent of LV hyper-
trophy [HR 1.59 (1.06–2.38), P ¼ 0.026] and Framingham
risk score [HR 1.05 (1.0321.07), P ¼ 0.001]. In a second
model, time-varying LV hypertrophy and concentric geome-
try were replaced by LV geometric patterns as time-varying
categories. In this model, the rate of combined cardiovascu-
lar events was three-fold higher with time-varying LV con-
centric remodelling, 1.8-fold higher with time-varying
eccentric LV hypertrophy, and 2.7-fold higher with time-
varying concentric LV hypertrophy (all P , 0.05), indepen-
dent of signiﬁcant effects of Framingham risk score, race,
and time-varying systolic blood pressure (Table 4). Adding
history of cardiovascular disease or time-varying heart rate
to the variables in the model did not change the results.
When evaluating the three individual components of the
combined primary endpoint using similar models, risk of
stroke was signiﬁcantly associated with concentric remodel-
ling, whereas risk of cardiovascular death was associated
with eccentric LV hypertrophy as well as concentric remo-
delling, and risk of myocardial infarction with both eccentric
and concentric LV hypertrophy, respectively (all P, 0.05)
(Table 4). In an additional model, time-varying change in
LV mass/body surface area replaced time-varying LV geome-
try. In this model, larger time-varying reduction in LV mass/
body surface area was associated with lower rate of the









Age (years) 64+7 65+7 66+7* 67+7†
Women (%) 37 43 41 45
Diabetes (%) 9 12 12 11
African American (%) 19 11 12 17
Body mass index (kg/m2) 26.9+3.7 27.4+4.7 27.4+4.5 27.1+4.5
Systolic blood pressure (mmHg) 169+14 169+14 175+15† 177+14†
Diastolic blood pressure (mmHg) 97+9 99+9 98+9 99+9
Heart rate (bpm) 68+13 70+12 66+12 68+11
Albuminuria (%) 13 21† 27† 34†
LV end-diastolic volume (ml) 123+19 100+14† 161+34† 118+20
LV end-systolic volume (ml) 45+13 34+7† 70+26† 43+14
LV mass/body surface area (g/m2) 98+11 99+10 134+22 135+24
RWT 0.38+0.03 0.46+0.03 0.37+0.04 0.49+0.06
Aortic regurgitation (%) 8 10 16* 17*
LV, left ventricular; LVH, left ventricular hypertrophy; RWT, relative wall thickness.
*P , 0.05; †P , 0.01 vs. normal geometry.
Figure 1 Left ventricular geometry at baseline and after 4.8 years
antihypertensive treatment. CR, concentric remodelling; C-LVH,
concentric LV hypertrophy; E-LVH, eccentric LV hypertrophy; N,
normal geometry.













combined primary end-point [HR 0.89 per 10 g/m2 reduction
in LV mass/body surface area (0.81–0.97), P ¼ 0.009] inde-
pendent of signiﬁcant associations with higher baseline LV
mass/body surface area and Framingham risk score and
lower time-varying systolic blood pressure (all P , 0.01).
As illustrated in Figure 2, using ﬁndings on the last event-
free re-evaluation in individual patients, each pattern of
abnormal LV geometry was associated with higher rate of
cardiovascular events.
Discussion
This study reports on the association of in-treatment LV geo-
metry with cardiovascular events in hypertensive patients
participating in a randomized treatment study. The study
has several interesting ﬁndings adding to previous publi-
cations on the prognostic signiﬁcance of reduction in LV
hypertrophy in clinical trials assessed by either serial echo-
cardiograms or electrocardiograms.3–5,26,27 First, in-treat-
ment LV geometric patterns predict risk of cardiovascular
events in hypertensive patients with baseline LV hypertrophy
measured by electrocardiography, independent of other
potential confounders including age, race, diabetes, total
and high-density lipoprotein cholesterol levels, systolic
blood pressure, and antihypertensive treatment type. Sec-
ondly, in treated hypertensive patients, in-treatment con-
centric remodelling was signiﬁcantly associated with
cardiovascular mortality and risk of stroke, eccentric LV
hypertrophy with cardiovascular mortality and myocardial
infarction, and concentric LV hypertrophy with risk of myo-
cardial infarction, respectively.
The ﬁnding that in-treatment LV geometric patterns
during systematic antihypertensive treatment in the LIFE
hypertension treatment study predicted risk of subsequent
cardiovascular events is complementary to a previous
report by Muiesan et al.4 In their prospective study of cardi-
ovascular events in a group of 436 hypertensive patients,
patients with persistent or new development of concentric
LV geometry during follow-up had higher risk of cardiovascu-
lar morbidity and mortality.4 Although the wide conﬁdence
limits warrants caution in interpretation of prognostic infor-
mation by individual in-treatment LV geometric patterns,
the present study results, by demonstrating that concentric
remodelling as well as eccentric and concentric LV hypertro-
phy patterns all independently predict risk of combined car-
diovascular events (Table 4), adds to previous studies
suggesting that evaluation of LV geometry by echocardiogra-
phy in treated hypertensive patients may add to clinical risk









Age (years) 65+7 65+7 67+7* 69+7†
Women (%) 38 38 47† 51†
Diabetes (%) 9 38† 15† 12*
African American (%) 12 38† 14 35†
Body mass index (kg/m2) 27.3 þ 4.4 29.8 þ 7.4 27.5+4.6 27.5+4.6
Systolic blood pressure (mmHg) 143+16 147 þ 21 148+18† 161 þ 20†
Diastolic blood pressure (mmHg) 82+9 85 þ 8 82 þ 11 89 þ 16†
Heart rate (bpm) 68+11 71+12 67+13 73+10
Albuminuria (%) 18 54† 33† 35†
LV end-diastolic volume (ml) 137+27 104+19† 169+35† 115+19†
LV end-systolic volume (ml) 5619 37+10† 77+29† 43+12†
LV mass/body surface area (g/m2) 91+14 99+14 127+20 135+30
RWT 0.32+0.04 0.45+0.05 0.33+0.04 0.48+0.07
Aortic regurgitation (%) 14 13 27† 16*
LV, left ventricular; LVH, ventricular hypertrophy; RWT, relative wall thickness.
*P , 0.05; †P , 0.01 vs. normal geometry.










179 97 436 225 Final LV
geometry
Normal (n) 170 80 224 117 591
Concentric remodelling (n) 0 13 2 9 24
Eccentric LVH (n) 8 4 204 63 279
Concentric LVH (n) 1 0 6 36 43
LV, left ventricular; LVH, left ventricular hypertrophy.













stratiﬁcation and echocardiographic assessment of LV hyper-
trophy alone.1–5
Our ﬁnding that in-treatment concentric geometry was
associated with increased risk of stroke conﬁrms previous
ﬁndings reported by Verdecchia et al. who followed 694
hypertensive patients with normal LV mass for an average
of 2.3 years in the Progetto Ipertensione Umbria Monitorag-
gio Ambulatoriale (PIUMA) registry, ﬁnding that rate of car-
diovascular events was twice as high in patients with
concentric remodelling compared with patients with
normal LV geometry.1 Similar ﬁndings have also been
reported by Pierdomenico et al.28 However, our ﬁnding
that having in-treatment concentric remodelling carries
comparable risk of CV events to having in-treatment con-
centric hypertrophy differs from previous reports, and may
possibly be explained by higher prevalences of obesity, dia-
betes, albuminuria and African American ethnicity among
patients remaining with concentric remodelling pattern
compared with the other in-treatment LV geometric pat-
terns (Table 3).
Interestingly, as a consequence of higher in-treatment LV
mass/body surface area and RWT, in-treatment persistence
or development of concentric LV hypertrophy carried a
1.6-fold higher risk for fatal or non-fatal myocardial infarc-
tion than the risk associated with eccentric hypertrophy
(Table 4). These results are in accordance with previous
reports.1,4,29 The particularly high risk of myocardial infarc-
tion with concentric LV hypertrophy may be associated with
greater myocardial oxygen demand in this geometric group
leading to increasing muscle mass-blood supply mismatch
and more relative subendocardial ischaemia and lower myo-
cardial contractility in this group, as previously
reported.30,31 Furthermore, in hypertensive patients, coron-
ary blood ﬂow reserve has been demonstrated to be particu-
larly low in patients with concentric LV hypertrophy.32–34
The present study also demonstrates that LV geometry
changes substantially during aggressive antihypertensive
treatment (Figure 1). In particular, the prevalence of the
most disadvantageous geometric pattern, concentric LV
hypertrophy, was reduced by 82% (Table 3). In fact,
already after 1-year treatment, nearly half of the patients
with initial abnormal LV geometry had returned to having
normal LV geometry. Thus, it is not surprising that LV geome-
try at baseline did not predict risk of cardiovascular events
during ongoing antihypertensive treatment in the present
study.
A limitation of the present study is that it was conducted
in hypertensive patients complying with the speciﬁc
inclusion and exclusion criteria used in the main LIFE
study.6 In particular, all patients had LV hypertrophy docu-
mented on electrocardiograms prior to study enrolment.
However, the number of adults who would meet LIFE entry
criteria has been estimated at 7.8 million in the ﬁrst 15
member states of the European Union,35 with nearly as
many each in the remainder of Europe and in the USA.
In conclusion, antihypertensive treatment induces major
changes of LV geometry in hypertensive patients with elec-
trocardiographic LV hypertrophy, with especially marked
reductions in prevalences of concentric LV hypertrophy and
remodelling. In the present population, LV geometry at
baseline before randomized antihypertensive treatment
was started did not independently inﬂuence prognosis. In
contrast, the presence on in-treatment echocardiograms of
each of the three abnormal LV geometric patterns was
associated with higher risk of a subsequent combined
Figure 2 Time course of combined primary endpoints (cardiovas-
cular death, stroke, and myocardial infarction) in patient groups
with different left ventricular geometry at ﬁnal event-free
in-treatment echocardiogram (all patterns P , 0.001 vs. normal
geometry).
Table 4 Association of time-varying LV geometry with incidence of combined and individual cardiovascular death, stroke, and myocardial
infarction evaluated by time-varying Cox regression analysis
Combined CV







Time-varying CR 2.99 (1.16–7.71)* 7.85 (2.07–29.69)† 3.02 (1.05–8.68)*
Time-varying E-LVH 1.79 (1.17–2.73)† 3.24 (1.48–7.12)† 2.56 (1.33–4.99)† 1.00 (0.55–1.80)
Time-varying C-LVH 2.71 (1.13–6.45)* 2.82 (0.60–13.36) 4.00 (1.15–13.97)* 2.36 (0.89–6.26)
Time-varying systolic
blood pressure (mmHg)
0.99 (0.98–1.00)† 1.01 (0.99–1.03) 0.98 (0.96–1.00)* 1.01 (1.00–1.02)
Framingham risk score 1.04 (1.02–1.06)† 1.07 (1.04–1.11)† 1.02 (0.99–1.05) 1.04 (1.02–1.07)†
CR, concentric remodelling; CV, cardiovascular; E-LVH, eccentric LV hypertrophy; C-LVH, concentric LV hypertrophy.
*P , 0.05; †P , 0.01.
Results are presented as hazard ratios (95% conﬁdence intervals) and P-values for the individual variables in each model. No patients with concentric remo-
delling at ﬁnal study experienced myocardial infarction. Additional variables that did not enter any of the models: race and randomized study treatment.













endpoint of cardiovascular death, stroke, and myocardial
infarction independent of clinical and demographic confoun-
ders of cardiovascular risk in hypertension, including age,
gender, race, smoking, blood pressure, and serum choles-
terol. One or more of the abnormal LV geometric patterns
was also an independent predictor of cardiovascular
death, stroke, and myocardial infarction as separate
endpoints, despite diminished statistical power due to the
smaller number of events in these analyses.
Acknowledgement
We thank Paulette A. Lyle for assistance with the preparation of the
manuscript.
Conﬂict of interest: E.G., K.W., B.D. and R.B.D. have received
grant support and honoraria from Merck & Co., Inc. (Merck), the
sponsor of the LIFE study. B.D. and R.B.D. also serve on Merck’s
speaker’s bureau and are members of an advisory board for Merck.
Funding
This study was supported by grant COZ-368 from Merck & Co., Inc.
References
1. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of
left ventricular mass and geometry to morbidity and mortality
in uncomplicated essential hypertension. Ann Intern Med 1991;114:
345–52.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic impli-
cations of echocardiographically determined left ventricular mass in the
Framingham Heart Study. N Engl J Med 1990;332:1561–6.
3. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C
et al. Adverse prognostic signiﬁcance of concentric remodeling of the left
ventricle in hypertensive patients with normal left ventricular mass. J Am
Coll Cardiol 1995;25:871–8.
4. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S et al. Left
ventricular concentric geometry during treatment adversely affects car-
diovascular prognosis in hypertensive patients. Hypertension 2004;43:
731–8.
5. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS,
Papademetriou V et al. Prognostic signiﬁcance of left ventricular mass
change during treatment of hypertension. JAMA 2004;292:2350–6.
6. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J et al.
Echocardiographic left ventricular geometry in hypertensive patients
with electrocardiographic left ventricular hypertrophy: The LIFE study.
Blood Press 2001;10:74–82.
7. Dahlo¨f B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U et al.
The Losartan Intervention for Endpoint Reduction in Hypertension study.
Characteristics of 9194 patients with left ventricular hypertrophy: the
LIFE study. Hypertension 1998;32:989–97.
8. Dahlo¨f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al.
Cardiovascular morbidity and mortality in the Losartan Intervention for
Endpoint reduction in hypertension study (LIFE): a randomized trial
against atenolol. Lancet 2002;359:995–1003.
9. Devereux RB, Dahlo¨f B, Gerdts E, Boman K, Nieminen MS,
Papademetriou V et al. Regression of hypertensive left ventricular hyper-
trophy by losartan compared with atenolol: the Losartan Intervention for
Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:
1456–62.
10. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA
et al. Recommendations for chamber quantiﬁcation: a report from the
American Society of Echocardiography’s Guidelines and Standards Com-
mittee and the Chamber Quantiﬁcation Writing Group, developed in con-
junction with the European Association of Echocardiography, a branch of
the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:
1440–63.
11. Gutgesell HP, Paquet M, Duff DF, McNamara DG. Evaluation of left ventri-
cular size and function by echocardiography. Results in normal children.
Circulation 1977;56:457–62.
12. Reichek N, Devereux RB. Reliable estimation of peak left ventricular sys-
tolic pressure by M-mode echographic-determined end-diastolic relative
wall thickness: identiﬁcation of severe valvular aortic stenosis in adult
patients. Am Heart J 1982;103:202–3.
13. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardio-
graphic volume determinations: echocardiographic–angiographic corre-
lations in the presence of absence of asynergy. Am J Cardiol 1976;37:
7–11.
14. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al.
Echocardiographic assessment of left ventricular hypertrophy: compari-
son to necropsy ﬁndings. Am J Cardiol 1986;57:450–8.
15. Palmieri V, Dahlo¨f B, DeQuattro V, Sharpe N, Bella JN, de Simone G et al.
Reliability of echocardiographic assessment of left ventricular structure
and function: the PRESERVE study. Prospective Randomized Study Evalu-
ating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999;34:
1625–32.
16. Palmieri V, de Simone G, Arnett DK, Bella JN, Kitzman DW, Oberman A
et al. Relation of various degrees of body mass index in patients with sys-
temic hypertension to left ventricular mass, cardiac output, and periph-
eral resistance (The Hypertension Genetic Epidemiology Network Study).
Am J Cardiol 2001;88:1163–8.
17. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Relation of
arterial structure and function to left ventricular geometric patterns in
hypertensive adults. J Am Coll Cardiol 1996;28:751–6.
18. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH
et al. Assessment of left ventricular function by midwall fractional short-
ening/end-systolic stress relation in human hypertension (published
erratum appears in J Am Coll Cardiol 1994;24:844). J Am Coll Cardiol
1994;23:1444–51.
19. Gaasch WH, Zile MR, Hoshino PK, Apstein CS, Blaustein AS. Stress-
shortening relations and myocardial blood ﬂow in compensated and
failing canine hearts with pressure-overload hypertrophy. Circulation
1989;79:872–83.
20. Lebowitz NE, Bella JN, Roman MJ, Liu JE, Fishman DP, Paranicas M et al.
Prevalence and correlates of aortic regurgitation in American Indians: the
Strong Heart Study. J Am Coll Cardiol 2000;36:461–7.
21. European Society of Hypertension–European Society of Cardiology Guide-
lines Committee. 2003 European Society of Hypertension–European
Society of Cardiology guidelines for the management of arterial hyper-
tension. J Hypertens 2003;21:1011–53.
22. WHO Study Group. Diabetes Mellitus (technical report series 727).
Geneva: WHO; 1985.
23. Jensen JS, Clausen P, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B.
Detecting microalbuminuria by urinary albumin/creatinine concentration
ratio. Nephrol Dial Transplant 1997;12:6–9.
24. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk
proﬁle. A statement for health professionals. Circulation 1991;83:
356–62.
25. Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying
covariate with an extended Kaplan–Meier estimator. Am Statistician
2005;59:301–7.
26. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Qilong Y et al.
Reduction of cardiovascular risk by regression of electrocardiographic
markers of left ventricular hypertrophy by the angiotensin-converting
enzyme inhibitor ramipril. Circulation 2001;104:1615–21.
27. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS et al.
Regression of electrocardiographic left ventricular hypertrophy during
antihypertensive treatment and prediction of major cardiovascular
events. JAMA 2004;292:2343–9.
28. Pierdomenico SD, Lapenna D, Bucci A, Manente BM, Cuccurullo F,
Mezzetti A. Prognostic value of left ventricular concentric remode-
ling in uncomplicated mild hypertension. Am J Hypertens 2004;17:
1035–9.
29. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I
et al. Prognostic value of left ventricular mass and geometry in sys-
temic hypertension with left ventricular hypertrophy. Am J Cardiol
1996;78:197–202.
30. Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E et al.
Left ventricular wall stresses and wall stress-mass-heart rate products
in hypertensive patients with electrocardiographic left ventricular hyper-
trophy: the LIFE study. Losartan Intervention for Endpoint reduction in
hypertension. J Hypertens 2000;18:1129–38.
31. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH
et al. Assessment of left ventricular function by midwall fractional short-
ening/end-systolic stress relation in human hypertension. J Am Coll
Cardiol 1994;23:1444–51.













32. Hasebe N, Shen YT, Kiuchi K, Hittinger L, Bishop SP, Vatner SF. Enhanced
postischemic dysfunction selective to subendocardium in conscious dogs
with LV hypertrophy. Am J Physiol 1994;226:H702–13.
33. Galderisi M, de Simone G, Cicala S, De Simone L, D’Errico A, Caso P
et al. Coronary ﬂow reserve in hypertensive patients with
appropriate or inappropriate left ventricular mass. J Hypertens 2003;
21:2183–8.
34. Kozakova M, de Simone G, Morizzo C, Palombo C. Coronary vasodilator
capacity and hypertension-induced increase in left ventricular mass.
Hypertension 2003;41:224–9.
35. Dahlo¨f B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB et al.
Population impact of losartan use on stroke in the European Union (EU):
Projections from theLosartan Intervention for Endpoint reduction in hyper-
tension (LIFE) study. J Hum Hypertens 2004;18:367–73.






TECA CENTRALE on Novem
ber 25, 2010
ejechocard.oxfordjournals.org
D
ow
nloaded from
 
